How to Protect Children Around the World from Respiratory Syncytial Virus (RSV)

Sunday, April 27, 2025

10:45am – 12:15pm HST

Location: Convention Center: Kalākaua Ballroom C (Level 4)

CE: 1.5

Selected By: ASPR
Co-sponsored By: PIDS

Chair(s)

Janet Englund, MD (she/her/hers)

Professor of Pediatrics
Seattle Children’s Hospital
Seattle, Washington, United States
Yae-Jean Kim, MD, PhD, FISDA (she/her/hers)

Professor
Samsung Medical Center, SungKyunKwan University
Seoul, Republic of Korea

Disclosure(s):

Janet Englund, MD: Abbvie (Terminated, July 1, 2023) (Products/Services: Consultant); Astra Zeneca (Ongoing) (Products/Services: Consultant, Research Support including clinical trials & the principal or named investigator); Enanta (Ongoing) (Products/Services: Consultant); GlaxoSmithKline (Ongoing) (Products/Services: Consultant, Research Support including clinical trials & the principal or named investigator); Merck (Ongoing) (Products/Services: Consultant, Research Support including clinical trials & the principal or named investigator); Moderna (Ongoing) (Products/Services: Consultant, Research Support including clinical trials & the principal or named investigator); Pfizer (Ongoing) (Products/Services: Consultant, Research Support including clinical trials & the principal or named investigator, Speaker Honorarium including speakers bureau, symposia, and expert witness); Sanofi pasteur (Ongoing) (Products/Services: Consultant); Shionogi (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator)

Yae-Jean Kim, MD, PhD, FISDA: Janssen (Terminated, September 2, 2022) (Products/Services: Research Support including clinical trials & the principal or named investigator); Merck (Terminated, October 21, 2023) (Products/Services: Research Support including clinical trials & the principal or named investigator)

This session, titled "How to Protect Children Around the World from Respiratory Syncytial Virus (RSV)", will focus on global strategies for RSV prevention in young children, highlighting and comparing prophylaxis strategies in Western and Asian countries. The discussion will cover the epidemiology of RSV in different regions and the use of nirsevimab and maternal RSV vaccines, with insights from the U.S., Japan, and Vietnam.
Dr. Janet Englund will present the U.S. perspective, where both nirsevimab and maternal RSV vaccine are approved for all infants, and maternal RSV vaccine is widely accessible through government or private insurance. Dr. Chikara Ogimi will discuss strategies in Japan, where nirsevimab is limited to high-risk children, and maternal RSV vaccines are only available at the patient’s expense. Dr. Lien Anh Ha Do will focus on Vietnam, where RSV epidemiology differs significantly from the West, and high-cost treatments like nirsevimab are unaffordable, posing significant challenges for widespread prevention.
The panel, led by Dr. Janet Englund and Dr. YaeJean Kim, will explore disparities in access to RSV prophylaxis, including monoclonal antibodies and vaccines, and discuss future opportunities to expand protection, particularly for high-risk groups such as immunocompromised patients or older high-risk children.
This session will provide valuable insights into the current landscape of RSV prevention and the future potential for global implementation of universal RSV prophylaxis.

Learning Objectives:

Upon completion, participants will be able to describe the global epidemiology of RSV infections and their impact on children in both Western and Asian countries.
Upon completion, participants will be able to identify gaps in RSV prevention strategies, including monoclonal antibodies and vaccines, in Western and Asian healthcare systems.
Upon completion, participants will be able to evaluate the potential future use of RSV monoclonal antibodies and vaccines for high-risk groups, including immunocompromised patients.

Presentations:

10:45am – 11:05am HST

Nirsevimab and RSV Vaccine Implementation in the U.S.: Achieving Universal Infant and Maternal Coverage
Speaker: Janet Englund, MD (she/her/hers) – Seattle Children’s Hospital
11:05am – 11:30am HST

Challenges in RSV Prevention in Japan: Limited Access to Nirsevimab and Cost Barriers for Maternal Vaccination
Speaker: Chikara Ogimi, MD, PhD (he/him/his) – National Center for Child Health and Development
11:30am – 12:00pm HST

RSV Prevention in Vietnam and Asia: Epidemiological Differences and Barriers to Expensive Monoclonal Antibodies and Vaccines
Speaker: Lien Anh Ha Do, MD, PhD (she/her/hers) – Murdoch Children's Research Institute
12:00pm – 12:15pm HST

Discussion and Q & A
Speaker: Yae-Jean Kim, MD, PhD, FISDA (she/her/hers) – Samsung Medical Center, SungKyunKwan University
Speaker: Janet Englund, MD (she/her/hers) – Seattle Children’s Hospital